TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10221694

Group type: EXPERIMENTAL
Intervention: Erlangen metal catheter
Number of subjects: 320

Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both catheters
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Transvaginal-transmyometrial transfer
Number of subjects: 320
Study: 7880949

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement by a doctor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement by a nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of nurse and doctor measurements
Number of subjects: 0
Study: 2204739

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 386675

Group type: EXPERIMENTAL
Intervention: Enterobiotic (oxytetracycline + neomycin)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 75
Study: 30940426

Group type: EXPERIMENTAL
Intervention: Fluidotherapy (40 °C, 20 minutes in continuous mode, 5 sessions/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional rehabilitation program (5 days/week, 2‐4 hours/day)
Number of subjects: 30
Study: 28409530

Group type: EXPERIMENTAL
Intervention: Digital cervical stretching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no digital cervical stretching)
Number of subjects: 0
Study: 25443867

Group type: EXPERIMENTAL
Intervention: Staying Healthy‐Asthma Responsible & Prepared program
Number of subjects: 205

Group type: COMPARATOR
Intervention: All students (including control)
Number of subjects: 205
Study: 23712975

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (CET) program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 21856879

Group type: EXPERIMENTAL
Intervention: iScreen® photorefractive device
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: iScreen® photorefractive device in developmentally-at-risk children
Number of subjects: 169

Group type: COMPARATOR
Intervention: iScreen® photorefractive device in children without developmentally-at-risk factors
Number of subjects: 169
Study: 19884558

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) sleep intervention (Individualized Sleep Promotion Plan [ISPP])
Number of subjects: 219

Group type: COMPARATOR
Intervention: Healthy eating control (HEC)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT)
Number of subjects: 219
Study: 17438255

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 3600 mg/d for 8 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 135
Study: 16294457

Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐estradiol/0.125 mg trimegestone
Number of subjects: 13

Group type: COMPARATOR
Intervention: 2 mg 17beta‐estradiol/1 mg norethisterone acetate
Number of subjects: 13

Group type: COMPARATOR
Intervention: 1 mg 17beta‐estradiol/0.5 mg norethisterone acetate
Number of subjects: 13
Study: 12040347

Group type: EXPERIMENTAL
Intervention: Bivalirudin phase A (1.0 mg/kg bolus, infusion of 2.5 mg/kg/h for 4 hours) plus abciximab
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Bivalirudin phase B (0.5 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Bivalirudin phase C (0.75 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Number of subjects: 268

Group type: COMPARATOR
Intervention: Heparin plus planned abciximab
Number of subjects: 268
Study: 9883403

Group type: EXPERIMENTAL
Intervention: Paracervical anesthesia (10 ml of 1.5 mepivacaine)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 72
Study: 8584295

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times a day for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 21
Study: 2122724

Group type: EXPERIMENTAL
Intervention: Sorbitol (70%, 0 to 60 mL daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactulose (for 4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sorbitol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 30
Study: 392079

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg)
Number of subjects: 1705
Study: 31563483

Group type: EXPERIMENTAL
Intervention: Buffered local anaesthetic (10:1 dilution of 8.4% sodium bicarbonate with 2% lignocaine hydrochloride with adrenaline 1:80,000)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (2% lignocaine hydrochloride with adrenaline 1:80,000 without bicarbonate)
Number of subjects: 60
Study: 27808556

Group type: EXPERIMENTAL
Intervention: Parent-Focused Therapy (PFT)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills Program (CLAS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 199
Study: 28011807

Group type: EXPERIMENTAL
Intervention: 30-minute brief intervention delivered by school learning mentors and a leaflet on alcohol.
Number of subjects: 470

Group type: COMPARATOR
Intervention: Usual school-based practice and a leaflet on a healthy lifestyle (excluding alcohol).
Number of subjects: 470
Study: 25243536

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control
Number of subjects: 304
Study: 22510550

Group type: EXPERIMENTAL
Intervention: Short stretch support bandage, immobilized for four days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Two-layer compression bandage (Pro-Guide), mobilized one day after operation
Number of subjects: 38
Study: 20581801

Group type: EXPERIMENTAL
Intervention: Brain-computer interface-based games (20 sessions over 10 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Age- and gender-matched controls
Number of subjects: 10
Study: 17485423

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 15727575

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks and intranasal budesonide for 12 months
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery and intranasal budesonide for 12 months
Number of subjects: 109

Group type: COMPARATOR
Intervention: Spanish general population
Number of subjects: 109
Study: 12095905

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 2657

Group type: EXPERIMENTAL
Intervention: Self-rated health
Number of subjects: 2657

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 2657

Group type: EXPERIMENTAL
Intervention: Length of hospitalization
Number of subjects: 2657

Group type: EXPERIMENTAL
Intervention: Self-rated health (measured closest to time of death)
Number of subjects: 2657
Study: 10631762

Group type: EXPERIMENTAL
Intervention: 5 micrograms CCK‐4
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7595708

Group type: EXPERIMENTAL
Intervention: Vinorelbine (NVB) 30 mg/m2 weekly
Number of subjects: 183

Group type: COMPARATOR
Intervention: Melphalan (ALK) 25 mg/m2 every 4 weeks
Number of subjects: 183
Study: 2245951

Group type: EXPERIMENTAL
Intervention: morphine‐scopolamine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: pethidine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 101
Study: 382821

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 15
Study: 30571659

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 0
Study: 28857719

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate 70 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (all doses combined)
Number of subjects: 0
Study: 25425024

Group type: EXPERIMENTAL
Intervention: Activity stimulation programme during the child's first year
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no activity stimulation programme)
Number of subjects: 143
Study: 23610455

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard method (censored at time of death)
Number of subjects: 0
Study: 21305536

Group type: EXPERIMENTAL
Intervention: High-dose omeprazole (80-mg bolus followed by 8-mg/h infusion for 72 hours)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard-dose omeprazole (40-mg intravenous infusion once daily for 3 days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High-dose omeprazole
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard-dose omeprazole
Number of subjects: 122
Study: 19344191

Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 (5 microg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 (10 microg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neupogen (5 microg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Neupogen (10 microg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Filgrastim XM02 and Neupogen
Number of subjects: 36
Study: 17213880

Group type: EXPERIMENTAL
Intervention: Regular prenatal exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss programs incorporating diet and exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular exercise following conception
Number of subjects: 0
Study: 15253847

Group type: EXPERIMENTAL
Intervention: Intercessory prayer for 1 month directed toward a life concern or problem disclosed by the participant at baseline.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intercessory prayer).
Number of subjects: 86
Study: 11793037

Group type: EXPERIMENTAL
Intervention: IL-2 receptor antagonists (basiliximab and daclizumab)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No induction
Number of subjects: 35
Study: 9408981

Group type: EXPERIMENTAL
Intervention: Group 1: single daily dose of netilmicin based upon weight, age and renal function (mean dose 298 +/- 29 mg, median 300 mg, range 250-350 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2: 150% of standard dose (mean 418 +/- 45 mg, median 400 mg, range 350-500 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 3: 200% of standard dose (mean 525 +/- 41 mg, median 500 mg, range 400-550 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 4: 250% of standard dose (mean 710 +/- 39 mg, median 650 mg, range 600-750 mg)
Number of subjects: 80
Study: 8254242

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy added to best medical care including aspirin and control of manageable risk factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical care including aspirin and control of manageable risk factors
Number of subjects: 0
Study: 3545965

Group type: EXPERIMENTAL
Intervention: arbaprostil (10 micrograms q.i.d. for 4 wk)
Number of subjects: 82

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study: 31866488

Group type: EXPERIMENTAL
Intervention: Video decision support aid
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention-control arm (booklet about advance directives)
Number of subjects: 250
Study: 30893320

Group type: EXPERIMENTAL
Intervention: Dedicated hematology units
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Admission through hematology services
Number of subjects: 2330

Group type: COMPARATOR
Intervention: Dedicated emergency facilities
Number of subjects: 2330

Group type: COMPARATOR
Intervention: Observation facilities
Number of subjects: 2330
Study: 29354950

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication (once a day, five times per week, for 6 weeks, total 30 times)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (maintained original treatment with antihypertensive medication)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with medication
Number of subjects: 64
Study: 25257148

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine (quetiapine XR; 150 or 300 mg/day)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study: 23713578

Group type: EXPERIMENTAL
Intervention: Intensive treatment to lower blood pressure (target systolic level <140 mm Hg within 1 hour)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target systolic level <180 mm Hg)
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Intensive treatment to lower blood pressure
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline-recommended treatment
Number of subjects: 2839
Study: 21665546

Group type: EXPERIMENTAL
Intervention: recombinant LH (rLH) administration
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Late-follicular-phase LH concentration
Number of subjects: 475

Group type: COMPARATOR
Intervention: rLH administration
Number of subjects: 475
Study: 18298240

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 201
Study: 16239314

Group type: EXPERIMENTAL
Intervention: 30 seconds co-incubation (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 90 minutes co-incubation (group B)
Number of subjects: 81
Study: 14979510

Group type: EXPERIMENTAL
Intervention: Fastest pressurisation rate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Other pressurisation rates
Number of subjects: 15

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 15
Study: 11172114

Group type: EXPERIMENTAL
Intervention: Rollerball endometrial ablation
Number of subjects: 275

Group type: COMPARATOR
Intervention: Uterine balloon therapy
Number of subjects: 275
Study: 9292174

Group type: EXPERIMENTAL
Intervention: Endonasal surgery
Number of subjects: 31
Study: 8305662

Group type: EXPERIMENTAL
Intervention: Diltiazem 2 (2 micrograms/kg/min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diltiazem 1 (1 microgram/kg/min)
Number of subjects: 35
Study: 3521269

Group type: EXPERIMENTAL
Intervention: Moxalactam plus piperacillin
Number of subjects: 302

Group type: COMPARATOR
Intervention: Moxalactam plus amikacin
Number of subjects: 302
Study: 30322090

Group type: EXPERIMENTAL
Intervention: Snack replacement (n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Snack reduction (n = 22)
Number of subjects: 46
Study: 27072496

Group type: EXPERIMENTAL
Intervention: Graded glucose infusion (GGI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological effects
Number of subjects: 0
Study: 24735024

Group type: EXPERIMENTAL
Intervention: Dignity therapy + standard palliative care (SPC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard palliative care (SPC) alone
Number of subjects: 80
Study: 22020992

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg d-methamphetamine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20516483

Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo) with contrast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3D echocardiography (3D-echo) and DE-cMR
Number of subjects: 60
Study: 18172188

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT) with goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with external-beam radiotherapy (EBRT)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (ADT) with EBRT
Number of subjects: 456

Group type: COMPARATOR
Intervention: External-beam radiotherapy (EBRT) alone
Number of subjects: 456
Study: 15567450

Group type: EXPERIMENTAL
Intervention: Armagnac (30 ml/day for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vodka (same alcoholic strength, 30 ml/day for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Armagnac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Armagnac and Vodka
Number of subjects: 20
Study: 14608565

Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver (PRM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment (Control)
Number of subjects: 40
Study: 11706098

Group type: EXPERIMENTAL
Intervention: Citicoline (1000 mg PO twice a day for 6 weeks)
Number of subjects: 899

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 899
Study: 9501484

Group type: EXPERIMENTAL
Intervention: Underreporting group with brief information about validity scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Underreporting group with no information about validity scales
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard control group (no underreporting instructions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demographically matched group from the general population
Number of subjects: 0
Study: 7961535

Group type: COMPARATOR
Intervention: Fluoxetine 60 mg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg daily)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Fluoxetine (various doses: 20, 40, and 60 mg)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Fluoxetine (in responder extension)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Fluoxetine (open-label extension)
Number of subjects: 274
Study: 3567046

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: NDMC
Number of subjects: 0
Study: 31877362

Group type: EXPERIMENTAL
Intervention: Listening to recorded classical music for at least 30 minutes per day for 3 months.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 159
Study: 28866091

Group type: EXPERIMENTAL
Intervention: Sodium intake measured by 24-hour urine collections (mean intake 3,903 mg/day, standard deviation 1037 mg/day)
Number of subjects: 119
Study: 26936446

Group type: EXPERIMENTAL
Intervention: Tongue-pressure profile training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tongue-pressure strength and accuracy training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study: 24635691

Group type: EXPERIMENTAL
Intervention: PM-Prep (Peer-Mentored Prep)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control arm
Number of subjects: 82
Study: 22412088

Group type: EXPERIMENTAL
Intervention: Brachial infusion of NO synthase inhibitor (N(G)-monomethyl-l-arginine [L-NMMA])
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Brachial infusion of cytochrome P450 epoxygenase inhibitor (fluconazole)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of L-NMMA and fluconazole
Number of subjects: 58

Group type: COMPARATOR
Intervention: Heating-induced flow-mediated dilatation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Local plasma epoxyeicosatrienoic acids
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plasma nitrite
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Reactive oxygen species
Number of subjects: 58

Group type: COMPARATOR
Intervention: Plasma endothelin-1
Number of subjects: 58
Study: 20079863

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg/day orally for 6 months
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 147
Study: 18249106

Group type: EXPERIMENTAL
Intervention: EcoScreen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R‐Tube at ‐20 degrees C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R‐Tube at ‐70 degrees C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R‐Tube and Anacon
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Leukotriene B(4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cysteinyl‐leukotriene
Number of subjects: 12
Study: 16816277

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 306
Study: 12504694

Group type: EXPERIMENTAL
Intervention: High-pass resolution perimetry (HRP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology (FDT)
Number of subjects: 82
Study: 11078227

Group type: EXPERIMENTAL
Intervention: Adenosine (140 microg/kg/min for 6 minutes) and Heparin (10,000 U bolus)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8842597

Group type: EXPERIMENTAL
Intervention: DH Pressure Relief Walkers (DH)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total Contact Casts (TCCs)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Commercially available therapeutic shoes and removable walking casts
Number of subjects: 35
Study: 1299455

Group type: EXPERIMENTAL
Intervention: COOP Chart illustrations
Number of subjects: 177

Group type: COMPARATOR
Intervention: No illustrations
Number of subjects: 177
Study: 30883671

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine + 100 mcg of fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.125% levobupivacaine + 100 mcg of fentanyl
Number of subjects: 60
Study: 27979754

Group type: EXPERIMENTAL
Intervention: Integrative Medical Group Visits (IMGV) model
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 154